For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
BUSINESS
Kyowa Kirin’s Phozevel Now Available for Hyperphosphatemia
Kyowa Kirin is rolling out Phozevel (tenapanor) on February 20. Licensed from US partner Ardelyx, the drug is indicated for the improvement of hyperphosphatemia in chronic kidney disease patients on dialysis. Phozevel is a first-in-class phosphate absorption inhibitor designed to…
To read the full story
Related Article
- Listing OK’ed for Phesgo, Leqvio, Epkinly, and More; 30 Billion-Plus Yen Peak Sales for 3 Meds
November 16, 2023
- Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More
September 26, 2023
- Kyowa Kirin Files Hyperphosphatemia Drug in Japan
October 31, 2022
- Kyowa Kirin Gains Rights to NHE3 Inhibitor in Japan
November 29, 2017
BUSINESS
- AZ, Kyoto University to Study Pharmacovigilance Using RWD
November 5, 2024
- GRP Japan Acquires Hypoglycemia Drug Baqsimi from Lilly
November 5, 2024
- Meiji Seika Pharma “Preparing” to Sue CDP’s Haraguchi
November 5, 2024
- ROS1 Drug Effective in Japanese Subgroup: Nippon Kayaku
November 5, 2024
- Mitsubishi Tanabe Sales Up 6% on Radicava Oral Form
November 5, 2024
Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…